Dominic Smethurst - 02 Mar 2026 Form 4 Insider Report for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Reporting relationship: Chief Medical Officer
Issuer ticker: CRBP
Reported as of: 02 Mar 2026
Net transaction value: -$50,601
SEC form: 4
Accepted by SEC: 04 Mar 2026, 16:30:18 UTC
Prior SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Meghan Houghton, Attorney-in-Fact for Dominic Smethurst

Key filing fact

Dominic Smethurst filed Form 4 for Corbus Pharmaceuticals Holdings, Inc. (CRBP) on 04 Mar 2026.

Key facts

This page summarizes Dominic Smethurst's Form 4 filing for Corbus Pharmaceuticals Holdings, Inc. (CRBP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Mar 2026, 16:30.

Change

Previous filing in this sequence was filed on 04 Feb 2026.
Current net transaction value: -$50,601.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001820549 Primary reporting owner

Smethurst Dominic

Relationship: Chief Medical Officer
Address: C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD
Signature: /s/ Meghan Houghton, Attorney-in-Fact for Dominic Smethurst
Signature date: 04 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRBP transaction

Common Stock, par value $0.0001 per share

Sale

Transaction value: $50,601
Shares: -6,097
Change %: -6.4%
Price: $8.30
Shares after: 89,790
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Footnote F2

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

This amount includes 73,765 unvested RSUs subject to each grant's vesting schedule as previously reported.